The global kidney cancer diagnostics and therapeutics market is forecasted to grow at a CAGR of 5.64% from 2023 to 2028. The size of the market is predicted to be worth USD 5.1 billion by 2028 from USD 3.87 billion in 2023.
Though there has been considerable development in science and technology to tackle cancer, it continues to threaten lives worldwide. Kidney cancer is one of the frequent urologic tumors accounting for around 3% of all human cancers. The frequency rate of renal cell carcinoma has increased gradually in recent decades.
The rising adoption of advanced therapy techniques such as cytokine-based treatment primarily accelerates the growth rate of the global kidney cancer diagnostics and therapeutics market.
The growing economies of various countries are helping the healthcare industry grow at a high pace, further contributing to the growth of the global kidney cancer diagnostics and therapeutics market. Increasing demand for novel and effective diagnostics and therapeutics is another major factor catalyzing the growth of the Global Kidney Cancer Diagnostics and Therapeutics Market. Also, increased investments from governments and private organizations for research and development to develop minimally invasive techniques and the emergence of effective therapy procedures such as nephrectomy boost the global kidney cancer diagnostics and therapeutics market.
The emergence of novel and innovative diagnostics and therapeutic procedures such as cytokine and nephrectomy boosts the growth opportunities for key market players in this market, promoting growth during the forecast period across the world. The increasing prevalence of the geriatric population and growing demand for extensive diagnostics tests leads to the development and adoption of novel therapy procedures, which is creating several growth opportunities for the stakeholders operating in the global kidney cancer diagnostics therapeutics market. An increasing number of research and development activities for kidney cancer diagnostics and the emergence of technically advanced tests are likely to expand growth opportunities for the key players functioning in the international marketplace.
High costs associated with branded cancer drugs are the major challenge limiting the growth of the worldwide market. The increasing adoption rate of generic drugs is another major challenge restricting the development of the global kidney cancer diagnostics and therapeutics market.
Impact of COVID-19 on the global kidney cancer diagnostics and therapeutics market:
The SARS-CoV-2 reagent is responsible for the novel coronavirus (COVID-19) that has affected millions of human lives spreading to every corner of the world. The rapid spread of the coronavirus has caused drastic changes in the healthcare systems worldwide, impacting the patients affected by COVID-19. The kidney-related diagnosis and treatment procedures and all other elective surgeries were delayed. In general, patients with chronic renal diseases are at high risk of acute COVID-19 infections. Patients with renal cell carcinoma are more vulnerable to infections because of the disorders in the immune system.
Moreover, the COVID vaccination is proven to be effective and safe. The virus continues to impact patient care for patients suffering from renal cell carcinoma and other cancer diseases in multiple ways. Millions of cancer patients are battling COVID-19, and if any cancer patient is tested positive, they should make some efforts to delay surgeries until they recover fully. Cancer patients develop a small risk of allergic reaction to the COVID vaccine. Patients undergoing hemodialysis infected with COVID-19 need to continue their regimen and stay at their present center to reduce the risk of infection to other patients and healthcare personnel.
Market Size Available
2022 to 2028
2023 to 2028
By Type, Tests, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis, and Abbott Laboratories
This research report on the global kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented based on the type, tests, and region.
Kidney Cancer Diagnostics and Therapeutics Market – By Type:
The type of Renal Cell Carcinoma (RCC) is expected to account for the highest share in the kidney cancer diagnostics and therapeutics market. It is a type of kidney cancer. The RCC owes to the disease's high frequency, the existence of diagnostic procedures, and treatment therapies. RCC is most commonly seen in children and makes up 2% to 6% of childhood. RCC affects 70% of patients, and RCC's occurrence rate is high in North America. Around 270,000 new cases are diagnosed yearly, and out of those, 116,000 deaths take place. Regular renal cell carcinoma has been increasing steadily over the last twenty years. The factors responsible for RCC are lifestyle changes, genomic changes, and advancements in technology. Advanced Renal Cell Carcinoma therapeutics in Japan have achieved steady growth owing to the balance between the approval of combinational therapies and lifestyle changes.
Kidney Cancer Diagnostics and Therapeutics Market – By Tests:
Based on the tests, the biopsy and CT scan segments lead the growth in the market, holding 50% of the share in the market. Recent advancements like biopsy procedures are expected to provide healthy demand for kidney cancer diagnostics. The kidney Ultrasound segment is anticipated to lead the market, followed by biopsy and CT scan. High investments in research and development of kidney cancer diagnostics significantly enhance the accuracy of early-stage diagnostic tests boosting the segment growth in the kidney cancer diagnostic and therapeutics market globally.
Kidney Cancer Diagnostics and Therapeutics Market – By Region:
North America accounted for the largest share of the global Kidney Cancer Diagnostics and Therapeutics market, followed by Asia-Pacific and Europe. The frequency of this disease was higher in developed countries than in developing nations due to lifestyle factors. However, the Asia-Pacific region is anticipated to increase at the highest CAGR during the forecast period due to the low expense of drug production and the mounting patient base suffering from these diseases.
KEY MARKET PLAYERS:
Companies dominating the global kidney cancer diagnostics and therapeutics market profiled in this Market are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis, and Abbott Laboratories.
The current size of the kidney cancer diagnostics and therapeutics market worldwide is expected to be 3.87 billion in 2023.
The growth of the kidney cancer diagnostics and therapeutics market is primarily driven by factors such as increasing incidence of kidney cancer, advancements in diagnostic technologies, and the development of targeted therapies.
Some of the major players in the kidney cancer diagnostics and therapeutics market include Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Roche Holding AG, and Exelixis, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]